<i>FUS-ERG</i>+ AML is rare but has an extremely poor prognosis even with allo-HSCT in remission, possibly due to its a leukemia stem cell (LSC)-driven disease resulting in chemotherapy resistance and a novel therapy is urgently required. This evidence concerns the gene ERG and acute myeloid leukemia.